Objective:To discuss the risk factors in lung cancer patients with chemotherapy-induced severe neutropenia to provide reference for clinical drug use. Methods:A retrospective analysis was performed for the patients with lung cancer,and the risk factors of severe neutropenia were statistically analyzed and found out. Results:The results of single factor experiments showed that the incidence of severe neutropenia was related with radiotherapy history,cycles of chemotherapy and the use time of granulocyte colony factor. Based on a binary logistic regression analysis,the history of radiotherapy and the use of granulocyte colony factor were the significant risk factors of severe neutropenia in the lung cancer patients. Conclusion:For the patients with radiotherapy history,it is better to choose chemotherapy drugs with lower toxicity,decrease drug dosage or preventively use granulocyte colony factor. The rational use of rhG-CSF can alleviate chemotherapy-induced severe neutropenia.

To evaluate the medication for one patient with the infection by carbapenem-resistant escherichia coli (CRE) to provide reference for the treatment of drug-resistance bacteria in clinical practice. During the development of anti-infective treatment regimen, clinical pharmacists analyzed and evaluated the situation, and provided suggestions for the medication:amikacin combined with fosfomycin and tigecycline. Physician adopted the recommendations,and the infective symptoms obtained a better control. The participation of clinical pharmacists in the treatment of intractable infection practice can provide reasonable and effective medication recommendations for clinics to improve anti-infective effectiveness in clinics.